Progyny (PGNY) 2026 KeyBanc Capital Markets Healthcare Forum summary

Business performance and utilization trends

• Recent reduction in eligible lives was due to administrative adjustments, primarily from lower-utilizing clients, while new sign-ons are showing strong utilization rates.

• Utilization rates remain stable, typically in the 1.03–1.09% range, and are a more important metric than total eligible lives.

• Revenue guidance for the year is based on historical utilization patterns, with Q1 seeing the fewest high-revenue procedures and most activity ramping up in Q2–Q4.

• Forecasting incorporates years of client and industry data, with ongoing refinement as more cohorts are added.

Fully insured product launch and risk management

• The new fully insured product targets small group employers, with distribution through established broker and payer networks.

• Initial focus is on signing up distributors and training brokers ahead of the 2027 revenue launch.

• The product is premium-funded, excludes elective egg freezing, and includes utilization management and lifetime dollar maximums to control risk.

• Risk is further mitigated by annual premium adjustments and leveraging extensive data from existing small clients.

• Early adoption is expected to be slow, with acceleration as awareness and education increase among brokers.

Market opportunity, competition, and regulatory environment

• State mandates, such as California’s IVF coverage requirement, present significant growth opportunities in the fully insured market.

• Main barriers to entry are competition from large carriers and the need for broker education and awareness.

• The competitive landscape remains stable, with some smaller competitors facing financial challenges and even bankruptcy.

• The company continues to win the majority of new business and invests in enhancing its offering to maintain a competitive edge.